Unlocking the body's hidden healing potential
Frequency Therapeutics develops small molecule drugs that activate progenitor cells within the body to restore healthy tissue. Through the transitory activation of these progenitor cells, Frequency enables disease modification without the complexity of genetic engineering. Our lead program re-creates sensory cells in the inner ear to treat chronic noise induced hearing loss, which affects over 48 million people in the U.S. alone. Our platform technology is founded on discoveries in progenitor cell biology by Bob Langer, Sc.D. at MIT and Jeff Karp, Ph.D., at Harvard, with contributions from Xiaolei Yin, Ph.D. and other members of the Karp Lab at Harvard and Brigham & Women's Hospital.
Our initial focus is on chronic hearing loss, a potential $20 billion market with no effective therapeutic solution. Our breakthrough therapy uses a proprietary combination of small-molecule drugs to cause dormant inner ear progenitor cells to multiply and create new hair cells.
Frequency is actively engaged in developing additional products through strategic alliances and internal development, such as skin disorders, muscle regeneration and gastrointestinal diseases.